SCHEMBL3530352

SCHEMBL3530352

O=C(O)c1cncc(C(=O)NCO)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.54
KDM4E B2RXH2 8/20 0.49
ALDH1A1 P00352 5/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
HCAR2 Q8TDS4 5/20 0.48
POLB P06746 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
DDO Q99489 1/20 0.48
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
ATM Q13315 1/20 0.45
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5909197 0.92 THRB (0.61) THRBKDM4EALDH1A1POLBGAA
SCHEMBL9536808 0.80 SMN1; SMN2 (0.57) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
SCHEMBL51830 0.79 HCAR2 (0.70) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
Fluoride SCHEMBL21331909 0.77 HCAR2 (0.67) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
Hydrochloric Acid SCHEMBL1117746 0.77 HCAR2 (0.67) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
SCHEMBL19987838 0.77 HCAR2 (0.67) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
Hydrochloric Acid SCHEMBL7661020 0.77 HCAR2 (0.67) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
Bromide SCHEMBL21332093 0.77 HCAR2 (0.67) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
Hydrochloric Acid SCHEMBL7124062 0.77 HCAR2 (0.67) KDM4EALDH1A1CYP2C9CYP2C19HCAR2
SCHEMBL7652997 0.77 KDM4E (0.59) THRBKDM4EALDH1A1CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
CN-1744899-A Piperidine derivatives as CCR5 antagonists SMITHKLINE BEECHAM CORP (US) 2006-03-08 CN disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 THRB 1093/4885KDM4E 4644/4885ALDH1A1 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.